Research analysts at Craig Hallum began coverage on shares of Cardlytics (NASDAQ:CDLX) in a report released on Monday, MarketBeat reports. The brokerage set a “buy” rating and a $75.00 price target on the stock. Craig Hallum’s price objective indicates a potential upside of 21.52% from the company’s current price.
Other equities research analysts have also issued reports about the stock. JPMorgan Chase & Co. lowered shares of Cardlytics from an “overweight” rating to a “neutral” rating and set a $58.00 price objective for the company. in a report on Thursday, November 14th. They noted that the move was a valuation call. Zacks Investment Research upgraded shares of Cardlytics from a “hold” rating to a “buy” rating and set a $63.00 price objective on the stock in a research report on Monday, November 18th. SunTrust Banks boosted their target price on shares of Cardlytics from $25.00 to $35.00 and gave the stock a “buy” rating in a report on Friday, August 9th. ValuEngine lowered shares of Cardlytics from a “hold” rating to a “sell” rating in a research report on Wednesday, October 2nd. Finally, Raymond James upped their target price on shares of Cardlytics from $40.00 to $53.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 13th. One research analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company’s stock. Cardlytics has a consensus rating of “Buy” and a consensus target price of $48.86.
NASDAQ CDLX opened at $61.72 on Monday. Cardlytics has a twelve month low of $9.80 and a twelve month high of $61.98. The business has a 50-day moving average price of $46.78 and a 200-day moving average price of $33.98. The firm has a market cap of $1.41 billion, a price-to-earnings ratio of -28.84 and a beta of 1.71.
Cardlytics (NASDAQ:CDLX) last issued its earnings results on Tuesday, November 12th. The company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.31. Cardlytics had a negative return on equity of 44.53% and a negative net margin of 17.01%. The company had revenue of $56.42 million for the quarter, compared to the consensus estimate of $50.02 million. During the same quarter last year, the company earned ($0.15) EPS. The firm’s quarterly revenue was up 63.2% on a year-over-year basis. On average, sell-side analysts forecast that Cardlytics will post -1.01 earnings per share for the current fiscal year.
In other Cardlytics news, Director Bryce Youngren sold 100,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $58.91, for a total transaction of $5,891,000.00. Following the completion of the transaction, the director now owns 8,484 shares in the company, valued at approximately $499,792.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director David Leslie Adams sold 23,750 shares of Cardlytics stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $58.75, for a total value of $1,395,312.50. Following the completion of the sale, the director now directly owns 41,770 shares in the company, valued at approximately $2,453,987.50. The disclosure for this sale can be found here. Over the last quarter, insiders purchased 316,475 shares of company stock worth $11,914,849 and sold 926,561 shares worth $37,775,884. 21.90% of the stock is currently owned by insiders.
Institutional investors and hedge funds have recently modified their holdings of the company. Grantham Mayo Van Otterloo & Co. LLC bought a new position in shares of Cardlytics during the 2nd quarter valued at approximately $10,392,000. Bank of America Corp DE raised its stake in Cardlytics by 17.6% during the second quarter. Bank of America Corp DE now owns 338,915 shares of the company’s stock valued at $8,805,000 after purchasing an additional 50,621 shares in the last quarter. Antipodean Advisors LLC bought a new position in Cardlytics during the second quarter valued at $3,698,000. JPMorgan Chase & Co. lifted its position in Cardlytics by 177.9% during the second quarter. JPMorgan Chase & Co. now owns 199,301 shares of the company’s stock valued at $4,901,000 after purchasing an additional 127,596 shares during the last quarter. Finally, Royal Bank of Canada lifted its position in Cardlytics by 166.5% during the second quarter. Royal Bank of Canada now owns 10,643 shares of the company’s stock valued at $276,000 after purchasing an additional 6,649 shares during the last quarter. 93.17% of the stock is currently owned by institutional investors and hedge funds.
Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.
Featured Article: What is a Special Dividend?
Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.